|1.||Gil, Esther Garcia: 11 articles (01/2015 - 05/2010)|
|2.||Caracta, Cynthia: 9 articles (01/2014 - 01/2011)|
|3.||Garcia Gil, Esther: 6 articles (01/2014 - 03/2012)|
|4.||Garcia Gil, E: 6 articles (06/2012 - 07/2009)|
|5.||Jones, Paul W: 5 articles (06/2015 - 01/2011)|
|6.||Gavaldà, Amadeu: 5 articles (02/2014 - 08/2009)|
|7.||Caracta, Cynthia F: 5 articles (01/2014 - 01/2012)|
|8.||Bateman, Eric D: 4 articles (01/2015 - 01/2011)|
|9.||Singh, Dave: 4 articles (01/2015 - 10/2012)|
|10.||Miralpeix, Montserrat: 4 articles (02/2014 - 08/2009)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
03/01/2014 - "Other benefits of aclidinium bromide therapy, including a significant reduction in nighttime COPD symptoms, were demonstrated for up to one year. "
10/01/2014 - "Overall, aclidinium bromide has been found to be safe and effective for the treatment of moderate-to-severe COPD. "
01/01/2012 - "The aim of this review is to provide an overview of the clinical studies evaluating the safety and efficacy of inhaled aclidinium bromide, a novel long-acting anticholinergic bronchodilator, for the treatment of COPD. "
02/13/2012 - "Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile."
07/07/2014 - "This short review provides an overview of studies evaluating the efficacy of aclidinium bromide, a long-acting anticholinergic bronchodilator, for the treatment of COPD. "
|2.||Obstructive Lung Diseases (Obstructive Lung Disease)
12/01/2012 - "The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease."
07/01/2013 - "Aclidinium bromide inhalation powder (tudorza): a long-acting anticholinergic for the management of chronic obstructive pulmonary disease."
07/01/2013 - "Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease."
04/01/2015 - "Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease."
|3.||Dyspnea (Shortness of Breath)
06/01/2013 - "Pivotal Phase III trials have documented that aclidinium bromide 400 μg twice-daily shows clinically meaningful effects in lung function and other important supportive outcomes, such as health-related quality of life, dyspnea and night-time/early morning symptoms, and is safe. "
12/01/2012 - "Aclidinium bromide is a novel long-acting antimuscarinic bronchodilator; Phase III clinical trials have demonstrated that administration of this drug twice per day improves lung function, dyspnea and health-related quality of life. "
01/01/2014 - "This study evaluated the effects of aclidinium bromide, a long-acting muscarinic antagonist indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD), on exercise endurance, dyspnea, lung hyperinflation, and physical activity. "
01/01/2012 - "Compared with other long-acting bronchodilators, including tiotropium bromide, aclidinium bromide leads to at least similar clinically important improvements in level of FEV(1), health status, use of rescue medication, and day-time dyspnea scores in patients suffering from moderate to severe COPD. "
|4.||Asthma (Bronchial Asthma)
06/01/2011 - "Aclidinium bromide in experimental asthma."
12/15/2010 - "In the present study, we investigated whether a novel long-acting cholinergic antagonist, aclidinium bromide, modulates airway function and leukocyte trafficking in an Aspergillus fumigatus (Af)-induced murine model of asthma. "
06/01/2011 - "Aclidinium bromide is an inhaled compound in the same class as tiotropium, which is currently being investigated in chronic obstructive pulmonary disease and asthma. "
01/01/2014 - "Several long-acting anticholinergic bronchodilators are under investigation or are available for the treatment of respiratory diseases, including tiotropium bromide, aclidinium bromide, glycopyrronium bromide, glycopyrrolate and umeclidinium bromide, although none is yet licensed for the treatment of asthma. "
03/01/2014 - "Aclidinium bromide (Tudorza, Forest Pharmaceuticals) is indicated for long-term maintenance therapy for COPD-associated bronchospasm. "
12/01/2013 - "Aclidinium bromide is a long-acting muscarinic antagonist approved for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). "
|3.||Cholinergic Antagonists (Anticholinergics)
|4.||Glycopyrrolate (Glycopyrronium Bromide)
|6.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|8.||Bronchodilator Agents (Bronchodilators)
|9.||dasatinib (BMS 354825)
|1.||Dry Powder Inhalers
|2.||Nebulizers and Vaporizers (Inhaler)